I was recently featured in SFGate’s medical analysis responding to a widely publicized study published in JAMA Cardiology. Conducted by researchers at the University of California, San Francisco (UCSF), the study suggested associations between cannabis use and increased risks of coronary artery disease, acute myocardial infarction, and arrhythmias. While the study raised essential questions regarding public health and cardiovascular vigilance, I shared several critical concerns regarding its methodology, epidemiological confounding, and scientific framing—particularly regarding older adult patients using standardized cannabis under physician guidance.

To the lead author’s tremendous credit, he reached out to me directly following my public commentary. We engaged in a collegial, thoughtful physician-to-physician dialogue regarding the complexities of real-world patient data, the limitations of administrative health records, and the vital necessity of separating combustion hazards from pure cannabinoid pharmacology.

1. A Closer Look at the JAMA Cardiology Study: Scientific Strengths and Methodological Blindspots

Whenever an observational study linking cannabis to cardiovascular disease makes national headlines, patients and clinicians must look beyond the sensationalized abstracts to examine the underlying data architecture:

• Conflating Combustion with Cannabinoid Molecules: The vast majority of observational registry data in the UCSF study examined patients who consumed cannabis primarily via combustible smoking. Inhaling burning plant matter introduces polycyclic aromatic hydrocarbons, carbon monoxide, particulate matter, and volatile toxins into the pulmonary vasculature—compounds with well-documented atherogenic, endothelial-damaging, and pro-thrombotic properties. Blaming the cannabinoid molecules for the vascular damage caused by carbon monoxide and combustion smoke is scientifically unsound.
• The Uncontrolled Confounder of Polysubstance Co-Use: Large administrative health registries frequently fail to adequately control for concurrent or past tobacco use, alcohol consumption, illicit stimulant exposure (e.g., cocaine or amphetamines), sedentary lifestyles, and chronic dietary stressors. Residual confounding remains an inescapable limitation in non-randomized epidemiological cohorts.
• The “Sick User” Phenomenon (Reverse Causality): In real-world medicine, older adults frequently initiate cannabis therapy to manage severe chronic neuropathic pain, refractory insomnia, cancer-related distress, or treatment-resistant anxiety—conditions that are themselves independent risk factors for systemic inflammation and cardiovascular disease. Attributing pre-existing vascular vulnerability solely to cannabis initiation reverses the direction of clinical causality.

2. Biological Mechanisms: The Endocannabinoid System in the Cardiovascular Tree

Cannabinoid receptors are deeply integrated throughout the human cardiovascular system, expressed on vascular endothelial cells, cardiac myocytes, vascular smooth muscle cells, and presynaptic autonomic nerve terminals:

1. Autonomic Nervous System Biphasic Shift: When delta-9-THC is consumed at moderate to high doses, it triggers an immediate surge in sympathetic nervous system outflow while inhibiting parasympathetic (vagal) tone. This shifts the cardiac workload, precipitating transient resting tachycardia. Over several hours or with chronic low-dose exposure, sympathetic tone wanes, leading to vagal dominance, vasodilation, and potential orthostatic drops in blood pressure.
2. Coronary Perfusion & Endothelial Shear Stress: While cannabinoids are potent vasodilators in peripheral vascular beds, acute sympathetic stimulation can induce coronary microvascular constriction in susceptible patients with advanced endothelial dysfunction, temporarily lowering the threshold for exercise-induced angina.
3. Platelet Aggregation and Thrombosis: Platelets express both CB1 and CB2 receptors. Current translational research indicates that high concentrations of synthetic or combustion-derived CB1 agonists may enhance platelet activation, whereas whole-plant cannabidiol (CBD) and minor cannabinoids attenuate platelet aggregation and protect against ischemic reperfusion injury.

3. Clinical Risk Stratification: High-Risk Populations & Contraindications

In clinical practice, responsible cannabinoid medicine requires rigorous cardiac screening. We stratify patients into clear risk categories:

• Absolute Contraindications for High-THC Formulations:
  • Acute Coronary Syndrome or Myocardial Infarction within the preceding 6 months
  • Unstable Angina Pectoris
  • Symptomatic, uncontrolled ventricular arrhythmias or recurrent paroxysmal atrial fibrillation
  • Severe aortic stenosis or decompensated congestive heart failure (NYHA Class III or IV)
• Relative Precautions & Clinical Adaptations: Patients with well-controlled hypertension, stable coronary artery disease, or mild dyslipidemia can safely utilize cannabinoid therapy under structured physician oversight. In these populations, we mandate non-inhalation delivery formats (sublingual tinctures or oral formulations), prioritize CBD-dominant or balanced Type II chemovars, and initiate therapy with conservative micro-titration (1.0 to 2.0 mg of active cannabinoid).

4. Clinical Harm Reduction & Cardiovascular Medication Interactions

For patients with cardiovascular disease seeking cannabinoid therapy for chronic pain, neuropathy, or sleep disruption, three fundamental clinical rules protect cardiac safety:

1. Eliminate Combustion Completely: Smoking cannabis flower delivers carbon monoxide, which binds to hemoglobin with 200 times the affinity of oxygen, reducing myocardial oxygen delivery. Vaporizing at low temperatures or utilizing sublingual drops eliminates combustion byproducts entirely.
2. Screen Hepatic CYP450 Drug Interactions: Many cardiovascular drugs are cleared by hepatic enzymes that interact with cannabinoids:
   • Warfarin: CBD and THC inhibit CYP2C9, which can elevate INR levels and increase bleeding risks. Close prothrombin time monitoring is mandatory.
   • Statins (Atorvastatin, Simvastatin): Competitively cleared by CYP3A4; high doses of CBD can increase systemic statin bioavailability, elevating risk of myopathy.
   • Beta-Blockers & Calcium Channel Blockers: Can produce synergistic reductions in peripheral vascular resistance, necessitating blood pressure monitoring to prevent symptomatic hypotension. Check baseline medications via the CED Clinic CYP450 Interaction Checker.
3. Evening Dosing & Hydration Protocols: Dosing in the evening while seated or in bed minimizes the risk of orthostatic dizziness upon standing. Ensuring adequate hydration supports intravascular volume and stabilizes blood pressure.

Frequently Asked Questions: Cannabis & Heart Health

Written & Medically Reviewed by Benjamin Caplan, MD

ABFM Board-Certified Family Physician | MA Medical License #240562 | NPI: 1962722637
Founder & CMO of CED Clinic & CED Foundation | Author of The Doctor-Approved Cannabis Handbook

Dr. Benjamin Caplan has evaluated over 350,000 patients across his career, specializing in cardiovascular harm reduction, complex chronic disease, and clinical pharmacokinetics. For personalized medical consultations, explore CED Clinic or read his comprehensive analysis on the CED Clinic Cardiovascular Study Deep Dive.